<?xml version="1.0" encoding="UTF-8"?>
<patent-document ucid="EP-2680821-A2" country="EP" doc-number="2680821" kind="A2" date="20140108" family-id="46045037" file-reference-id="317508" date-produced="20180823" status="corrected" lang="EN"><bibliographic-data><publication-reference fvid="146586840" ucid="EP-2680821-A2"><document-id><country>EP</country><doc-number>2680821</doc-number><kind>A2</kind><date>20140108</date><lang>EN</lang></document-id></publication-reference><application-reference ucid="EP-12719451-A" is-representative="NO"><document-id mxw-id="PAPP154849032" load-source="docdb" format="epo"><country>EP</country><doc-number>12719451</doc-number><kind>A</kind><date>20120303</date><lang>EN</lang></document-id><document-id mxw-id="PAPP168045839" load-source="docdb" format="original"><country>EP</country><doc-number>12719451.2</doc-number><date>20120303</date><lang>EN</lang></document-id></application-reference><priority-claims><priority-claim mxw-id="PPC140547724" ucid="IB-2012051014-W" linkage-type="W" load-source="docdb"><document-id format="epo"><country>IB</country><doc-number>2012051014</doc-number><kind>W</kind><date>20120303</date></document-id></priority-claim><priority-claim mxw-id="PPC140550493" ucid="PL-39408211-A" load-source="docdb"><document-id format="epo"><country>PL</country><doc-number>39408211</doc-number><kind>A</kind><date>20110303</date></document-id></priority-claim></priority-claims><technical-data><classifications-ipcr><classification-ipcr mxw-id="PCL1989318048" load-source="docdb">A61K  31/375       20060101ALI20131004BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989319189" load-source="docdb">A61K  31/519       20060101ALI20131004BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989320173" load-source="docdb">A61K   9/127       20060101AFI20131004BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989321266" load-source="docdb">A61K  45/06        20060101ALI20131004BHEP        </classification-ipcr></classifications-ipcr><classifications-cpc><classification-cpc mxw-id="PCL2039492164" load-source="docdb" scheme="CPC">A61K  31/375       20130101 LI20140228BHEP        </classification-cpc><classification-cpc mxw-id="PCL2039494008" load-source="docdb" scheme="CPC">A61K   9/1278      20130101 LI20140228BHEP        </classification-cpc><classification-cpc mxw-id="PCL2039495571" load-source="docdb" scheme="CPC">A61K  45/06        20130101 LI20140228BHEP        </classification-cpc><classification-cpc mxw-id="PCL2039495920" load-source="docdb" scheme="CPC">A61K   9/127       20130101 FI20140220BHEP        </classification-cpc><classification-cpc mxw-id="PCL2039496968" load-source="docdb" scheme="CPC">A61K   9/1271      20130101 LI20140228BHEP        </classification-cpc><classification-cpc mxw-id="PCL2039498311" load-source="docdb" scheme="CPC">A61K  31/704       20130101 LI20140220BHEP        </classification-cpc><classification-cpc mxw-id="PCL2039499377" load-source="docdb" scheme="CPC">A61K  31/519       20130101 LI20140228BHEP        </classification-cpc></classifications-cpc><invention-title mxw-id="PT132365153" lang="DE" load-source="patent-office">LIPOSOMENFORMULIERUNG MIT ANTITUMORWIRKSTOFF, VERFAHREN ZU IHRER HERSTELLUNG UND DIESE ENTHALTENDE PHARMAZEUTISCHE ZUSAMMENSETZUNGEN</invention-title><invention-title mxw-id="PT132365154" lang="EN" load-source="patent-office">LIPOSOME FORMULATION COMPRISING AN ANTI-TUMOUR ACTIVE SUBSTANCE, METHOD FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING IT</invention-title><invention-title mxw-id="PT132365155" lang="FR" load-source="patent-office">FORMULATION LIPOSOMALE COMPRENANT UNE SUBSTANCE ACTIVE ANTITUMORALE, PROCÉDÉ DE PRÉPARATION ET COMPOSITIONS PHARMACEUTIQUES LA COMPRENANT</invention-title></technical-data><parties><applicants><applicant mxw-id="PPAR919527240" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>WROCLAWSKIE CT BADAN EIT &amp; SP Z O O</last-name><address><country>PL</country></address></addressbook></applicant><applicant mxw-id="PPAR919526250" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>WROCLAWSKIE CENTRUM BADAN EIT + SP Z O.O.</last-name></addressbook></applicant><applicant mxw-id="PPAR919018723" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Wroclawskie Centrum Badan EIT + SP Z O.O.</last-name><iid>101406116</iid><address><street>ul. Stablowicka 147</street><city>54-066 Wroclaw</city><country>PL</country></address></addressbook></applicant></applicants><inventors><inventor mxw-id="PPAR919532377" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>GUBERNATOR JERZY</last-name><address><country>PL</country></address></addressbook></inventor><inventor mxw-id="PPAR919529561" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>GUBERNATOR, JERZY</last-name></addressbook></inventor><inventor mxw-id="PPAR919019619" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>GUBERNATOR, JERZY</last-name><address><street>Kamieniecka 66</street><city>50-511 Wroclaw</city><country>PL</country></address></addressbook></inventor><inventor mxw-id="PPAR919533622" load-source="docdb" sequence="2" format="epo"><addressbook><last-name>Kozubek Arkadiusz</last-name><address><country>PL</country></address></addressbook></inventor><inventor mxw-id="PPAR919540221" load-source="docdb" sequence="2" format="intermediate"><addressbook><last-name>KOZUBEK, ARKADIUSZ</last-name></addressbook></inventor><inventor mxw-id="PPAR919010586" load-source="patent-office" sequence="2" format="original"><addressbook><last-name>KOZUBEK, ARKADIUSZ</last-name><address><street>Godebskiego 48/2</street><city>51-691 Wroclaw</city><country>PL</country></address></addressbook></inventor><inventor mxw-id="PPAR919531144" load-source="docdb" sequence="3" format="epo"><addressbook><last-name>PADUSZYNSKI PIOTR</last-name><address><country>PL</country></address></addressbook></inventor><inventor mxw-id="PPAR919529535" load-source="docdb" sequence="3" format="intermediate"><addressbook><last-name>PADUSZYNSKI, PIOTR</last-name></addressbook></inventor><inventor mxw-id="PPAR919011051" load-source="patent-office" sequence="3" format="original"><addressbook><last-name>PADUSZYNSKI, PIOTR</last-name><address><street>13-go Grudnia 6</street><city>98-346 Skomlin</city><country>PL</country></address></addressbook></inventor><inventor mxw-id="PPAR919509745" load-source="docdb" sequence="4" format="epo"><addressbook><last-name>LIPKA DOMINIK</last-name><address><country>PL</country></address></addressbook></inventor><inventor mxw-id="PPAR919506864" load-source="docdb" sequence="4" format="intermediate"><addressbook><last-name>LIPKA, DOMINIK</last-name></addressbook></inventor><inventor mxw-id="PPAR919016830" load-source="patent-office" sequence="4" format="original"><addressbook><last-name>LIPKA, DOMINIK</last-name><address><street>ul. Krasinskiego 4/43</street><city>32-305 Olkusz</city><country>PL</country></address></addressbook></inventor></inventors><agents><agent mxw-id="PPAR919016900" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Witek, Rafal</last-name><iid>101319982</iid><address><street>WTS Patent Attorneys Witek, Sniezko &amp; Partners ul. Rudolfa Weigla 12</street><city>53-114 Wroclaw</city><country>PL</country></address></addressbook></agent></agents></parties><international-convention-data><pct-or-regional-filing-data ucid="IB-2012051014-W"><document-id><country>IB</country><doc-number>2012051014</doc-number><kind>W</kind><date>20120303</date><lang>EN</lang></document-id></pct-or-regional-filing-data><pct-or-regional-publishing-data ucid="WO-2012117385-A2"><document-id><country>WO</country><doc-number>2012117385</doc-number><kind>A2</kind><date>20120907</date><lang>EN</lang></document-id></pct-or-regional-publishing-data><designated-states><ep-contracting-states><country mxw-id="DS549765464" load-source="docdb">AL</country><country mxw-id="DS549846712" load-source="docdb">AT</country><country mxw-id="DS549765473" load-source="docdb">BE</country><country mxw-id="DS549777047" load-source="docdb">BG</country><country mxw-id="DS549860502" load-source="docdb">CH</country><country mxw-id="DS549765874" load-source="docdb">CY</country><country mxw-id="DS549846713" load-source="docdb">CZ</country><country mxw-id="DS549916795" load-source="docdb">DE</country><country mxw-id="DS549765474" load-source="docdb">DK</country><country mxw-id="DS549765875" load-source="docdb">EE</country><country mxw-id="DS549847137" load-source="docdb">ES</country><country mxw-id="DS549777048" load-source="docdb">FI</country><country mxw-id="DS549777053" load-source="docdb">FR</country><country mxw-id="DS549765475" load-source="docdb">GB</country><country mxw-id="DS549765476" load-source="docdb">GR</country><country mxw-id="DS549765481" load-source="docdb">HR</country><country mxw-id="DS549846790" load-source="docdb">HU</country><country mxw-id="DS549860503" load-source="docdb">IE</country><country mxw-id="DS549765482" load-source="docdb">IS</country><country mxw-id="DS549777054" load-source="docdb">IT</country><country mxw-id="DS549765876" load-source="docdb">LI</country><country mxw-id="DS549916796" load-source="docdb">LT</country><country mxw-id="DS549846791" load-source="docdb">LU</country><country mxw-id="DS549916797" load-source="docdb">LV</country><country mxw-id="DS549916798" load-source="docdb">MC</country><country mxw-id="DS549845153" load-source="docdb">MK</country><country mxw-id="DS549845162" load-source="docdb">MT</country><country mxw-id="DS549847142" load-source="docdb">NL</country><country mxw-id="DS549846792" load-source="docdb">NO</country><country mxw-id="DS549847143" load-source="docdb">PL</country><country mxw-id="DS549846793" load-source="docdb">PT</country><country mxw-id="DS549847144" load-source="docdb">RO</country><country mxw-id="DS549765893" load-source="docdb">RS</country><country mxw-id="DS549847145" load-source="docdb">SE</country><country mxw-id="DS549765894" load-source="docdb">SI</country><country mxw-id="DS549845163" load-source="docdb">SK</country><country mxw-id="DS549845164" load-source="docdb">SM</country><country mxw-id="DS549860504" load-source="docdb">TR</country></ep-contracting-states></designated-states></international-convention-data><office-specific-data><eptags><ep-no-a-document-published>*</ep-no-a-document-published></eptags></office-specific-data></bibliographic-data><abstract mxw-id="PA99835228" ref-ucid="WO-2012117385-A2" lang="EN" load-source="patent-office"><p num="0000">The subject of the present invention is a liposomal formulation containing an anti-tumour compound characterised in that it contains the active compound encapsulated in liposome vesicles forming a composition of lipid components in the ratio of 1 part by mass of the active compound per 5 parts by mass of the lipid components, preferably 1 part by mass of the active compound per 5 parts by mass of the lipid components as well as a vitamin or a derivative thereof, a method of producing it as well as composition containing the said formulation.</p></abstract><abstract mxw-id="PA100331062" ref-ucid="WO-2012117385-A2" lang="EN" source="national office" load-source="docdb"><p>The subject of the present invention is a liposomal formulation containing an anti-tumour compound characterised in that it contains the active compound encapsulated in liposome vesicles forming a composition of lipid components in the ratio of 1 part by mass of the active compound per 5 parts by mass of the lipid components, preferably 1 part by mass of the active compound per 5 parts by mass of the lipid components as well as a vitamin or a derivative thereof, a method of producing it as well as composition containing the said formulation.</p></abstract><abstract mxw-id="PA99835229" ref-ucid="WO-2012117385-A2" lang="FR" load-source="patent-office"><p num="0000">La présente invention concerne une formulation liposomale contenant un composé antitumoral caractérisé en ce qu'elle contient le composé actif encapsulé dans les vésicules liposomales formant une composition de composants lipidiques au rapport de 1 partie en poids du composé actif pour 5 parties en poids des composants lipidiques, de préférence de 1 partie en poids du composé actif pour 5 parties en poids des composants lipidiques ainsi qu'une vitamine ou un dérivé de celle-ci, un procédé de production ainsi qu'une composition contenant ladite formulation.</p></abstract><abstract mxw-id="PA100331063" ref-ucid="WO-2012117385-A2" lang="FR" source="national office" load-source="docdb"><p>La présente invention concerne une formulation liposomale contenant un composé antitumoral caractérisé en ce qu'elle contient le composé actif encapsulé dans les vésicules liposomales formant une composition de composants lipidiques au rapport de 1 partie en poids du composé actif pour 5 parties en poids des composants lipidiques, de préférence de 1 partie en poids du composé actif pour 5 parties en poids des composants lipidiques ainsi qu'une vitamine ou un dérivé de celle-ci, un procédé de production ainsi qu'une composition contenant ladite formulation.</p></abstract><description mxw-id="PDES51232910" ref-ucid="WO-2012117385-A2" lang="EN" load-source="patent-office"><!-- EPO <DP n="2"/>--><p id="p0001" num="0001"> Liposome formulation comprising an anti-tumour active substance, method for its preparation and pharmaceutical compositions comprising it </p><p id="p0002" num="0002">The subject of the present invention is a liposome formulation containing an anti-tumour active compound, a method of producing it and a pharmaceutical composition containing it, for use in medicine. </p><p id="p0003" num="0003">Liposomes are uni- or multilamellar closed structures in which a bilayer of an amphiphylic lipids encloses a microdrop of water (unilamellar liposomes) or else lipid membranes are formed concentrically and interspersed with aqueous layers (multilamellar liposomes). Amphiphylic lipids that form the bilayer possess a polar hydrophilic group and one or more linear hydrophobic polycarbon chains (&gt;C8) . The polar groups may be derivatives of phosphates, sulphates and nitrogen compounds, but the most commonly used ones are phospholipids, particularly those of natural origin, such as phosphatidylcholines obtained using the refinement of plant lipids, synthetic phospholipids, available commercially phospholipid formulations, including chemically modified phospholipids using derivatives of ethylene glycol and cholesterol. Depending on solubility, the medicinal substance is located in the aqueous layer or the lipid layer of the liposomes . There are several methods for liposomes production. A classic method of producing multilayer liposomes is based on evaporating a lipid-organic solvent solution and rehydration of the lipid film with an aqueous solution of the medicinal compound (J. Mol. Biol. 13 (1965), 238-252). Other techniques encompass the emulsification of a lipid into a two-phase mixture of an aqueous and organic phase containing the lipid, with the simultaneous evaporation of the organic solvent (e.g. 
<!-- EPO <DP n="3"/>-->
patent descriptions US 4,522,803, 5,030,453 and 5,169,637), formation of a water-in-oil emulsion, from which the organic phase is evaporated in order to produce a gel, which is then mixed to produce oligolamellar liposomes (US 4,235,871) as well as multiple freeze/thaw cycles (US 5,008,050). Unilamellar liposomes are obtained from multilamellar liposomes using ultrasounds, extrusion (e.g. US 4,975,282), homogenization, as well as injection of etheric or ethanol solutions of lipids into the aqueous phase (Deamer R., Uster, P. "Liposome preparation; Methods and Mechanisms", in: "Liposomes", ed. M.Ostro, Marcel Dekker, New York, 1987). </p><p id="p0004" num="0004">In the case of many groups of therapeutics, both the efficiency of enclosure of the active compound in vesicles as well as the stability of liposomes (in vitro and in vivo) are a serious technical problem. In particular, classical liposome formulations of highly insoluble in water taxoids, based on soya lecithin or a synthetic phospholipid analogue (Bartoli et al . J. Microencapsulation 7, 1990, 191-197, Riondel et al . In Vivo 6, 1992,23-28), exhibit a tendency to aggregate, as well as instability which causes the "leakage" of the active compound from the liposomes and its crystallization. In many cases, the manufacturing of a liposome formulations of the anti-tumour compounds with an effective lipid/drug ratio requires the use of special procedures, like for example described in the publication WO 9202208 and the application EP 546951 Al an addition of negatively charged phospholipids, or the addition of a polyhydroxy alcohol and quarternary ammonium salts as described in the Japanese patent description JP 06254379. Improved liposome structures ensuring greater stability through the steric stabilization of the surface of the lipid bilayer are achieved by the so-called "Stealth" liposomes (D. D. Lasic, F. Martin "Stealth Liposomes", CRC Press Boca Raton, 1995) . One method aimed at designing more 
<!-- EPO <DP n="4"/>-->
durable forms of liposomes is the use of a hydrophilic polyethylene glycol coating, as described in the publication of international application WO 9422429. Medicine has seen the introduction of a liposome-enclosed form of doxorubicin, coated with polyethylene glycol under the trade name Doxil®. This Doxil® preparation contains doxorubicin encapsulated in Stealth liposome carriers, composed of three lipid components: hydrogenated soya lecithin, cholesterol and a carbamate conjugate of distearylphosphatidylethanolamine with a methoxyl derivative of polyethylene glycol 2000 in an appropriate molar ratio. The long half-life of Stealth liposomes, together with low drug leakage, is obtained using unique encapsulation methods, which ensure high loading efficiency and long-term drug retention. These methods encompass loading with an electrolyte gradient (application EP 361894 Al) or pH gradient (publication WO 8806442) . In WO 8806442 publication, the components of the lipid layer constitute classic lipid compounds, such as natural and synthetic phosphatidylcholines, with the possible addition of cholesterol, and in the encapsulation process a pH gradient is used. According to the description, the limited leakage rate of the encapsulated biologically active compound is a result of the pH difference between the two sides of the lipid membrane. The pH gradient loading method is, however, limited solely to water phase soluble drugs, which are weak acids or bases. Liposome formulations containing topotecan and lipids in a 0.05:0.2 ratio, loaded using a pH gradient or ionophore loading method, are described in the publication WO 0202078. The lipid layer includes sphingomyelin and cholesterol. The international application WO 9915153 discloses, amongst others, taxol- containing liposomes, characterized by an active compound concentration in the liposomes no higher than 5 mg/ml and that contain the synthetic lecithin dilauroylphosphatidylcholine as the lipid. The authors declare that the drug: lipid ratio is in 
<!-- EPO <DP n="5"/>-->
the range from 1:1 to 1:2000, preferably 1:30, but present no information about the stability of these liposome formulations, meant for administering the anti-tumour compounds through inhalation. Stable liposome formulations have thus far been obtained mainly through the use of special procedures or active compound molecule modification, i.e. through the attachment of hydrocarbon, polymeric or peptide chains. In Polish patents Nos . 190077 and 190078 a high encapsulation efficiency of doxorubucin and mithoxanthrone at a preferable ratio of drug to lipid in a liposome formulation was obtained as a result of the lipid layer composition modification, which contains, in addition to classic components, egg lecithin and hydrogenated egg lecithin, a hydrogen sulphate acyl derivative of resorcine. Stable liposome formulations of paclitaxel have been obtained by the addition of cardiolipin to the lipid formulation (US patent descriptions Nos. 5,424,073, 5,648,090, 5,939,567 and 6,146,659). The description of US patent No. 6,146,659 discloses that in this case, the incorporation efficiency of paclitaxel in liposome vesicles exceeds 90%, with a mass ratio of active compound to lipid carrier of about 7%. In general, the possibility of incorporating paclitaxel into liposomes, as a result of its high hydrophobicity is limited to 1-10% (w/w), most often 2-8% (w/w) in relation to the lipid carrier. This coefficient can be improved only slightly (up to 12-14% w/w) as a result of the modification of paclitaxel molecule, e.g. through the attachment of hydrocarbon chains (US patent description Nos. 5,919,815, 5,939,567, 6, 118, 011) . There is thus still a need to design pharmaceutical liposome formulations, particularly liposome formulations containing a hydrophobic anti-tumour compounds, with a favourable lipid to active compound ratio, or ones facilitating the transfer of 
<!-- EPO <DP n="6"/>-->
the same amount of active compound by a smaller quantity of lipid carrier. </p><p id="p0005" num="0005">The second unmet need is the delivery of a liposome containing two anti-tumour compounds for the combined therapy with an increased therapeutic effect, and characterised by a high stability . </p><p id="p0006" num="0006">Unexpectedly, the aforementioned problems have been solved by the present invention. </p><p id="p0007" num="0007">The first subject of the present invention is a liposome formulation containing an anti-tumour compound characterised in that it contains an active compound enclosed in liposome vesicles forming a composition of lipid components in the ratio of 1 part by mass of the active compound per 3 to 12 parts by mass of lipid components, preferably 1 part by mass of the active compound per 5 parts by mass of lipid components as well as a vitamin or a derivative thereof. Preferably, a liposome formulation according to the present invention is characterised in that as the active compound it contains anthracyclines . Preferably, a liposome formulation according to the present invention is characterised in that the vitamin is ascorbic acid or a salt thereof, preferably ammonium ascorbate, folic acid or a salt thereof, preferably ammonium folate or pantothenic acid, preferably an ammonium salt thereof. Equally preferably, a liposome formulation according to the present invention is characterised in that vitamin derivative is methothrexate . </p><p id="p0008" num="0008">The second subject of the present invention is a method of producing liposome formulation with an anti-tumour active compound, characterised in that encompasses a) the formulation of unilamellar liposomes through the hydration of a phospholipid mixture, preferably hydrogenated 
<!-- EPO <DP n="7"/>-->
soya or egg lecithin or distearylphosphatidylcholine as well as cholesterol, preferably in an amount from 30 mg/ml to 60 mg/ml in a 300mM solution of a vitamin or its derivative, preferably an ammonium salt of ascorbic or folic or pantothenic acid; b) freezing and thawing of the suspension of liposomes in a solution of vitamin salt or its derivative, in liquid nitrogen and warm water, with a temperature above the phase transition temperature of the main lipid, in order to equalise the concentrations of vitamin salt or its derivative on both sides of the liposome bilayers; c) decreasing the size and layers of liposomes, preferably through extruding the liposomes through polycarbonate filters with appropriate pore size in a high pressure extruder, or through homogenizing in a high-pressure homogenizer; d) exchanging the external solution of the liposomes, preferably through dialysis or molecular sieving, to a neutral buffer, preferably PBS in order to form a pH and ionic gradient; e) addition of the anti-tumour active compound, preferably anthracycline ; f) heating the suspension to a temperature higher than the phase transition temperature of the main phospholipid forming the liposomes, preferably to 60 °C. </p><p id="p0009" num="0009">Equally preferably, a method according to the present invention is characterised in that during stage a) PEGylated phosphatidylethanolamine is added in order to stabilize the liposomes in the blood circulation system. Preferably a method according to the present invention is characterised in that the vitamin derivative used in stage a) is methothrexate or an ammonium salt thereof. 
<!-- EPO <DP n="8"/>-->
The third subject of the present invention is a pharmaceutical composition for parenteral administration encompassing a pharmaceutically permissible carrier and/or auxiliary compounds and a therapeutically effective amount of anti- tumour active compound, characterised in that it contains a liposome formulation containing an anti-tumour compound enclosed in liposome vesicles forming the composition of lipid components in the ratio of 1 part by mass of the active compound per 3 to 12 parts by mass of the lipid components, preferably 1 part by mass of the active compound per 5 parts by mass of the lipid components as well as a vitamin or a derivative thereof. Equally preferably, a composition according to the present invention is characterised in that it contains methothrexate or a salt thereof as well as a compound from among the anthracyclines . </p><p id="p0010" num="0010">A liposome according to the present invention is characterised by a desirable lipid/active compound ratio as well as a high encapsulation efficiency of the drug in liposomes after 5-10 minutes of the encapsulation process according to the method presented in the description. Additionally, a method according to the present invention makes it possible to prepare liposomes for the so-called combined therapy, where two different drugs are used in order to increase the therapeutic effect. Thus, in this case, one drug is used to encapsulate the second, obtaining as a consequence two drugs enclosed in the structure of a single liposome. This procedure additionally makes it possible to decrease the leakage of the vitamin derivative complex, e.g. methothrexate and anthracyclines, which stabilizes both drugs in the liposomes. In the case of methothrexate by itself, its leakage following intravenous administration may be too rapid due to the presence of aqueous drug solution, whereas the precipitated form of the drug is favoured for its greater stability. 
<!-- EPO <DP n="9"/>-->
Embodiments of the present invention are shown in the figures, wherein Fig. 1 represents a graph of the kinetics of the encapsulation of Epirubicin in HSPC/Chol/DSPE-PEG 2000 5.5:4:0.5 mol/mol liposomes due to the use of an ion gradient of 300 mM of an ammonium salt of ascorbic acid. The conditions of drug encapsulation are given in Example 1. A-C; Fig. 2 effect of the drug: lipid ratio on the Epirubicin encapsulation efficiency in HSPC/Chol/DSPE-PEG 2000 5.5:4:0.5 mol/mol liposomes due to the use of an ion gradient of 300 mM of an ammonium salt of ascorbic acid. The conditions of drug encapsulation are described in Example 2 A; Fig. 3 is the retention of Epirubicin in HSPC/Chol/DSPE-PEG 2000 5.5:4:0.5 mol/mol liposomes encapsulated using an ion gradient of 300 mM of an ammonium salt of ascorbic acid. The conditions of encapsulating the drugs are described in Example 3. A. and Fig. 4 represents the Epirubicin encapsulation efficiency in HSPC/Chol/DSPE-PEG 2000 5.5:4:0.5 mol/mol liposomes using an ion gradient of 300 mM of an ammonium salt of respectively folic acid, pantothenic acid as well as methothrexate . The conditions of drug encapsulation are as shown in Example 4. A- D. </p><p id="p0011" num="0011">Example 1 </p><p id="p0012" num="0012">A. Production of liposomes containing ascorbic acid. </p><p id="p0013" num="0013">A 100 ml round-bottomed flask was loaded with 35.28 mg hydrogenated soya lecithin (HSPC) and 13.02 mg cholesterol (Choi) as well as 11.67 mg PEGylated distearylphosphatidylethanolamine (DSPE-PEG 2000) in the form of chloroform solutions, and then organic solvent was evaporated using a vacuum evaporator. The dry lipid film was supplemented with a 1.5 ml solution of an ammonium salt of ascorbic acid (pH = 4,0) at a concentration of 300 mM, and then hydrated at a temperature of 64°C to the point when 
<!-- EPO <DP n="10"/>-->
multilamellar liposomes were obtained. </p><p id="p0014" num="0014">The liposome suspension was repeatedly frozen and thawed by alternating treating in liquid nitrogen and water with a temperature of 64°C, and then extruded in a pressure calibrator through a polycarbonate filter with a pore diameter of 100 nm at a temperature of 64°C. </p><p id="p0015" num="0015">B. Generation of an ion gradient of an ammonium salt of ascorbic acid. </p><p id="p0016" num="0016">Liposomes obtained in pt . A were loaded on a column (1x20 cm) filled with a Sephadex G-50 fine gel, equilibrated in PBS, and then desalted, at the same time exchanging the external solution (300 mM solution of an ammonium salt of ascorbic acid) for phosphate buffer (PBS, pH =7,4) . After separating the liposomes, the lipid concentration was determined using the Steward method. </p><p id="p0017" num="0017">C. Encapsulation of Epirubicin in HSPC/Chol/DSPE-PEG 2000 5.5:4:0.5 mol/mol liposomes. </p><p id="p0018" num="0018">A suspension of liposomes comprising HSPC/Chol/DSPE-PEG 2000 5.5:4:0.5 mol/mol containing 300 mM of ascorbic acid ammonium salt were supplemented with a solution of Epirubicin hydrochloride in 150 mM of NaCl at a concentration of 6 mg/ml in such an amount so that per 5 parts by mass of the lipid there was one part by mass of the drug. The suspension was mixed and heated for 60 minutes at a temperature of 60 °C collecting suspension samples at selected time intervals. Following incubation, we determined the encapsulation efficiency of the drug, which after 10 minutes was 98%. The experimental conditions were set so that the final lipid concentration was 15 mg/ml. A detailed description of the drug encapsulation is shown in Fig. 1 
<!-- EPO <DP n="11"/>-->
Example 2. </p><p id="p0019" num="0019">A. The effect of the drug lipid ratio on the encapsulation efficiency of Epirubicin in HSPC/Chol/DSPE-PEG 2000 5.5:4:0.5 mol/mol liposomes due to the use of an ion gradient 300 mM of an ammonium salt of ascorbic acid. </p><p id="p0020" num="0020">Liposomes were prepared as in Example 1. A-C, with the difference that the process of drug encapsulation was performed for several drug/lipid mass ratios; 1:5 (0.2) to 1:1 (1.0) . The time of drug encapsulation in each case was set at 10 minutes in 60 °C. After each incubation step, the liposomes were separated from unecapsulated drug in order to determine the encapsulation efficiency of the drug. The results obtained are shown in Fig. 2. </p><p id="p0021" num="0021">Example 3 A. Effect of storage time of liposomes in 4 °C on Epirubicin retention in HSPC/Chol/DSPE-PEG 2000 5.5:4:0.5 mol/mol liposomes in which the drug was encapsulated using an ion gradient of 300 mM of an ammonium salt of ascorbic acid. </p><p id="p0022" num="0022">Liposomes obtained as in Example 1 were incubated for 10 min in order to encapsulate the drug and then unencapsulated drug was separated from the liposomes on a mini column of 0.5X 7 cm filled with a Sephadex G-50 fine gel. The separated liposomes were collected and then, following the determination of the amount of lipid this was diluted with PBS buffer pH = 7,4 such that the final lipid concentration was 10 mg/ml. Liposomes were stored at 4 °C. From the resulting portions of liposomes, at selected intervals, were collected 50 μΐ samples of liposomes and then were separated in order to determine the amounts of freed drug. Data obtained are shown in Fig. 3. 
<!-- EPO <DP n="12"/>-->
Example 4. </p><p id="p0023" num="0023">A. Production of liposomes containing an ammonium salt of folic acid, pantothenic as well as methothrexate . </p><p id="p0024" num="0024">Liposomes were prepared as in Example 1. A-B with the difference that instead of a 300 mM solution of an ammonium salt of ascorbic acid, pH = 4.0 we used a 300 mM solution of an ammonium salt of folic acid, pH = 7.8 or a 300 mM solution of an ammonium salt of acid pantothenic acid pH = 7.8 or a 300 mM solution of an ammonium salt of methothrexate. B. Encapsulation of Epirubicin in HSPC/Chol/DSPE-PEG 2000 5.5:4:0.5 mol/mol liposomes using an ion gradient of an ammonium salt of folic acid. </p><p id="p0025" num="0025">A suspension of liposomes comprising HSPC/Chol/DSPE-PEG 2000 5.5:4:0.5 mol/mol containing a 300 mM ammonium salt of folic acid was supplemented with a solution of Epirubicin hydrochloride in 150 mM of NaCl at a concentration of 6 mg/ml, in such an amount so that for 5 parts by mass of the lipid there was one part by mass of the drug. The suspension was mixed and heated for 10 minutes at a temperature of 60 °C. Following incubation we determined the efficiency of drug encapsulation, which was 99%. The experimental conditions were set so that the final lipid concentration was 15 mg/ml. A detailed description of the drug encapsulation process is shown in Fig. 4. C. Encapsulation of Epirubicin in HSPC/Chol/DSPE-PEG 2000 5.5:4:0.5 mol/mol liposomes using an ion gradient of an ammonium salt of pantothenic acid. </p><p id="p0026" num="0026">Encapsulation of drug in liposomes was performed as in Example 4. B, with the difference that the liposomes contained not 300 mM of folic acid ammonium salt pH = 7.8, but 300 mM ammonium 
<!-- EPO <DP n="13"/>-->
salt of pantothenic acid. The efficiency of drug encapsulation was 97%. </p><p id="p0027" num="0027">D. Encapsulation of Epirubicin in HSPC/Chol/DSPE-PEG 2000 5.5:4:0.5 mol/mol liposomes using an ion gradient of 300 mM of an ammonium salt of methothrexate pH =7.8. </p><p id="p0028" num="0028">Encapsulation of drug in liposomes was performed as in Example 4. B with the exception that the liposomes contained not 300 mM folic acid ammonium salt pH = 7.8, but 300 mM of methothrexate ammonium salt. The drug encapsulation efficiency was 97%. </p><p id="p0029" num="0029">The encapsulation results obtained in points B-D, for 300 mM salts of folic acid, pantothenic as well as methothrexate are shown in Fig. 4. 
</p></description><claims mxw-id="PCLM44852075" ref-ucid="WO-2012117385-A2" lang="EN" load-source="patent-office"><claim-statement><!-- EPO <DP n="14"/>-->Claims </claim-statement><claim id="clm-0001" num="1"><claim-text>1. A liposomal formulation containing an anti-tumour compound characterised in that it contains an active compound enclosed in liposome vesicles forming a composition of lipid components in the ratio of 1 part by mass of the active compound per 5 parts by mass of the lipid components, preferably 1 part by mass of the active compound per 5 parts by mass of the lipid components as well as a vitamin or a derivative thereof. </claim-text></claim><claim id="clm-0002" num="2"><claim-text>2. A liposomal formulation according to Claim 1, characterised in that as the active compound it contains anthracyclines . </claim-text></claim><claim id="clm-0003" num="3"><claim-text>3. A liposomal formulation according to Claim 4, characterised in that the vitamin is ascorbic acid or a salt thereof, preferably ammonium ascorbate, folic acid or a salt thereof, preferably ammonium folate or pantothenic acid, preferably an ammonium salt thereof. </claim-text></claim><claim id="clm-0004" num="4"><claim-text>4. A liposomal formulation according to any of Claims from 1 to 3 characterised in that the vitamin derivative is methothrexate . </claim-text></claim><claim id="clm-0005" num="5"><claim-text>5. A method of producing a liposome formulation with an anti- tumour active compound, characterised in that it encompasses a) formulation of multilamellar liposomes through the hydration of a mixture of phospholipids, preferably hydrogenated soya or egg lecithin or distearylphosphatidylcholine as well as cholesterol, preferably in an amount from 30 mg/ml to 60 mg/ ml in a 300mM solution of the vitamin or its derivative, preferably an ammonium salt of ascorbic or folic or pantothenic acid; b) freezing and thawing of the suspension of liposomes in a <!-- EPO <DP n="15"/>--> solution of vitamin salt or its derivative in liquid nitrogen and warm water, with a temperature above the phase transfer temperature of the main lipid, in order to equilibrate the concentrations of vitamin salt or its derivative on both sides of the liposome mebranes; c) decreasing the size and layer counts of the liposomes, preferably by extruding the liposomes through polycarbonate filters of appropriate pore sizes in a high pressure extruder, or homogenizing in a high pressure homogenizer; d) exchanging the external solution of the liposomes, preferably through dialysis or molecular sieving, for a neutral buffer, preferably PBS in order to create the pH/ionic gradient ; e) adding the anti-tumour active compound, preferably anthracycline ; f) heating the suspension to a temperature greater than the phase transition temperature of the main phospholipid forming the liposomes, preferably to 60 °C. </claim-text></claim><claim id="clm-0006" num="6"><claim-text>6. A method according to Claim 5 characterised in that during stage a) PEGylated phosphatidylethanolamine is added in order to stabilize the liposomes in the blood circulation system. </claim-text></claim><claim id="clm-0007" num="7"><claim-text>7. A method according to Claim 5 or 6 characterised in that the vitamin derivative used in stage a) is methothrexate or an ammonium salt thereof </claim-text></claim><claim id="clm-0008" num="8"><claim-text>8. A pharmaceutical composition for parenteral administration encompassing a pharmaceutically permissible carrier and/or auxiliary compounds and a therapeutically effective amount of anti-tumour active compound, characterised in that it contains a liposome formulation containing the anti-tumour compound <!-- EPO <DP n="16"/>--> enclosed in liposome vesicles forming a composition of lipid components in the ratio of 1 part by mass of the active compound per 3 to 12 parts by mass of the lipid components, preferably 1 part by mass of the active compound per 5 parts by mass of the lipid components as well as a vitamin or a derivative thereof. </claim-text></claim><claim id="clm-0009" num="9"><claim-text>9. A composition according to Claim 9 characterised in that contains methothrexate or a salt thereof as well as a compound from among the anthracyclines . </claim-text></claim></claims><copyright>User acknowledges that Fairview Research LLC and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws.  User acquires no ownership rights to this xml including but not limited to its format.  User hereby accepts the terms and conditions of the Licence Agreement</copyright></patent-document>
